Gibson Christopher's Form 4 filing
Recursion Pharmaceuticals, Inc. (RXRX) · filed Mar 6, 2023
- Accession no.
- 0001209191-23-016450
- Filed
- Mar 6, 2023
- Trade date
- Mar 2, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions and 4 derivative transactions. Open-market sales total $166.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gibson ChristopherCIK 0001856369 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Class A Common Stock | CConversionAcquired | +18,500 | $0.00 | $0 | 956,427 | Direct | |
| Mar 2, 2023 | Class A Common Stock | SSaleDisposed | −18,500 | $7.92F3 | −$146,520 | 940,927 | Direct | |
| Mar 2, 2023 | Class A Common Stock | CConversionAcquired | +500 | $0.00 | $0 | 500 | Indirect | |
| Mar 2, 2023 | Class A Common Stock | SSaleDisposed | −500 | $7.90F5 | −$3,950 | 0 | Indirect | |
| Mar 2, 2023 | Class A Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Mar 2, 2023 | Class A Common Stock | SSaleDisposed | −1,000 | $7.91F7 | −$7,910 | 0 | Indirect | |
| Mar 2, 2023 | Class A Common Stock | CConversionAcquired | +1,000 | $0.00 | $0 | 1,000 | Indirect | |
| Mar 2, 2023 | Class A Common Stock | SSaleDisposed | −1,000 | $7.91F9 | −$7,910 | 0 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 2, 2023 | Class A Common Stock | CConversionDisposed | −18,500 | $0.00 | $0 | 6,621,834 | Direct | |
| Mar 2, 2023 | Class A Common Stock | CConversionDisposed | −500 | $0.00 | $0 | 539,000 | Indirect | |
| Mar 2, 2023 | Class A Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 528,000 | Indirect | |
| Mar 2, 2023 | Class A Common Stock | CConversionDisposed | −1,000 | $0.00 | $0 | 124,875 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $7.73 to $8.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $7.73 to $8.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F7
This transaction was executed in multiple trades at prices ranging from $7.74 to $8.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $7.75 to $8.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.